Clinical profiles of chronic lymphocytic leukaemia patients with SF3B1 mutations: A single-institution study.
Oncogenic SF3B1 mutations alter the splicing of mRNA noncoding regions to induce a novel therapeutic vulnerability.
Mis-splicing-derived neoantigens and cognate TCRs in splicing factor mutant leukemias
Mis-splicing-derived neoantigens and cognate TCRs in splicing factor mutant leukemias.
Induction of a mismatch repair deficient genotype by tailored chemical mutagenesis in experimental models of cancer.
Evaluating serum free light chain ratio as a biomarker in multiple myeloma.
Clinical profiles of chronic lymphocytic leukaemia patients with <i>SF3B1</i> mutations: A single‐institution study
Steering research on mRNA splicing in cancer towards clinical translation
Steering research on mRNA splicing in cancer towards clinical translation.
Evaluating serum free light chain ratio as a biomarker in multiple myeloma
Mis-Splicing Derived Neoantigens and Cognate T Cell Receptors in Splicing Factor Mutant Myeloid Neoplasms
Author Correction: Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors.
E7820, an anti-cancer sulfonamide, degrades RBM39 in patients with splicing factor mutant myeloid malignancies: a phase II clinical trial
Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signatures.
E7820, an anti-cancer sulfonamide, degrades RBM39 in patients with splicing factor mutant myeloid malignancies: a phase II clinical trial.
Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures
Systematic evaluation of AML-associated antigens identifies anti-U5 SNRNP200 therapeutic antibodies for the treatment of acute myeloid leukemia.
Waldenström macroglobulinemia whole genome reveals prolonged germinal center activity and late copy number aberrations.
Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors.
Sustained Minimal Residual Disease Negativity in Multiple Myeloma is Associated with Stool Butyrate and Healthier Plant-Based Diets
Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis.
Sustained Minimal Residual Disease Negativity in Multiple Myeloma is Associated with Stool Butyrate and Healthier Plant-Based Diets.
Pharmacologic modulation of RNA splicing enhances anti-tumor immunity
Pharmacologic modulation of RNA splicing enhances anti-tumor immunity.
Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma
Minor intron retention drives clonal hematopoietic disorders and diverse cancer predisposition
Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial
Minor intron retention drives clonal hematopoietic disorders and diverse cancer predisposition.
Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma: The MANHATTAN Nonrandomized Clinical Trial.
Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial.